Search

Your search keyword '"De Becker, Ann"' showing total 179 results
Start Over Author "De Becker, Ann"
179 results on '"De Becker, Ann"'

4. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

Author

Finke, Jürgen, Schaap, Nicolaas Petrus Michael, Zucenka, Andrius, Metzelder, Stephan, Jost, Edgar, Perić, Zinaida, Forghieri, Fabio, Allione, Bernadino, Martelli, Maurizio, Iori, Anna Paola, Wittnebel, Sebastian, Mengarelli, Andrea, Imovilli, Annalisa, Olivieri, Attilio, De Prijck, Bernard José Marie, van der Poel, Marjolein W.M., Junghanß, Christian, Salih, Helmut Rainer, Tafuri, Agostino, Guimarães, José Eduardo, Musso, Maurizio, De Fabritiis, Paolo, Chevallier, Patrice, Selleslag, Dominik Luc, Cascavilla, Nicola, Berneman, Zwi, Jaspers, Aurélie, Zuffa, Eliana, Vanstraelen, Gaëtan, Visani, Giuseppe, Cuijpers, Maria Louisa Henriëtte, De Becker, Ann, Mianulli, Anna Maria, Hackanson, Björn, Mihaylov, Georgi Georgiev, Martinelli, Giovanni, Paolini, Stefania, Zinzani, Pier Luigi, Henkes, Martin, Al-Ali, Haifa Kathrin, La Rosée, Paul, Chierichini, Anna, Cudillo, Laura, Specchia, Giorgina, Šimec, Njetočka Gredelj, Capalbo, Silvana Franca, Spinosa, Giuseppina, Molica, Stefano, de Jonge-Peeters, Susan Dorothé, Lübbert, Michael, Wijermans, Pierre W, Kicinski, Michal, Chantepie, Sylvain, Van der Velden, Walter J F M, Noppeney, Richard, Griškevičius, Laimonas, Neubauer, Andreas, Crysandt, Martina, Vrhovac, Radovan, Luppi, Mario, Fuhrmann, Stephan, Audisio, Ernesta, Candoni, Anna, Legrand, Olivier, Foà, Robin, Gaidano, Gianluca, van Lammeren-Venema, Danielle, Posthuma, Eduardus F M, Hoogendoorn, Mels, Giraut, Anne, Stevens-Kroef, Marian, Jansen, Joop H, de Graaf, Aniek O, Efficace, Fabio, Ammatuna, Emanuele, Vilque, Jean-Pierre, Wäsch, Ralph, Becker, Heiko, Blijlevens, Nicole, Dührsen, Ulrich, Baron, Frédéric, Suciu, Stefan, Amadori, Sergio, Venditti, Adriano, and Huls, Gerwin

Published
2023
Full Text
View/download PDF

5. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Author

Drozd-Sokolowska, Joanna, Gras, Luuk, Zinger, Nienke, Zahrani, Mohsen Al, Passweg, Jakob, Byrne, Jenny, Ho, Aloysius, Huang, Xiao-jun, Kröger, Nicolaus, Mayer, Jiri, Russo, Domenico, De Becker, Ann, Tbakhi, Abdelghani, Stamatoullas, Aspasia, Valerius, Thomas, Hayden, Patrick, McLornan, Donal P., Onida, Francesco, Scheid, Christof, Robin, Marie, and Yakoub-Agha, Ibrahim

Published
2023
Full Text
View/download PDF

6. Listeria monocytogenes Infections in Hematopoietic Cell Transplantation Recipients: Clinical Manifestations and Risk Factors. A Multinational Retrospective Case-Control Study from the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Author

Averbuch, Dina, Tridello, Gloria, Wendel, Lotus, Itälä-Remes, Maija, Oren, Ilana, Karas, Michal, Blijlevens, Nicole, Beguin, Yves, Broers, Annoek, Calore, Elisabetta, Cattaneo, Chiara, Isaksson, Cecilia, Robin, Christine, Gadisseur, Alain, Maertens, Johan, De Becker, Ann, Lueck, Catherina, Metafuni, Elisabetta, Pichler, Herbert, Popova, Marina, Ram, Ron, Yeshurun, Moshe, Mikulska, Malgorzata, Camara, Rafael de la, and Styczynski, Jan

Published
2024
Full Text
View/download PDF

9. Listeria monocytogenes infections in hematopoietic cell transplant recipients: clinical manifestations and risk factors: A multinational retrospective case control study of the Infectious Diseases Working Party (IDWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Author

Averbuch, Dina, primary, Tridello, Gloria, additional, Wendel, Lotus, additional, Itälä-Remes, Maija, additional, Oren, Ilana, additional, Karas, Michal, additional, Blijlevens, Nicole, additional, Beguin, Yves, additional, Broers, Annoek, additional, Calore, Elisabetta, additional, Cattaneo, Chiara, additional, Isaksson, Cecilia, additional, Robin, Christine, additional, Gadisseur, Alain, additional, Maertens, Johan, additional, De Becker, Ann, additional, Lueck, Catherina, additional, Metafuni, Elisabetta, additional, Pichler, Herbert, additional, Popova, Marina, additional, Ram, Ron, additional, Yeshurun, Moshe, additional, Mikulska, Malgorzata, additional, Camara, Rafael de la, additional, and Styczynski, Jan, additional

Published
2024
Full Text
View/download PDF

10. Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS)

Author

Poiré, Xavier, Graux, Carlos, Ory, Aurélie, Herman, Julie, Baron, Frédéric, Schoemans, Hélène, Lewalle, Philippe, De Becker, Ann, Deeren, Dries, Berneman, Zwi, Kerre, Tessa, Zachée, Pierre, Selleslag, Dominik, and Beguin, Yves

Published
2022
Full Text
View/download PDF

11. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice—data from a Belgian registry

Author

Devos, Timothy, Havelange, Violaine, Theunissen, Koen, Meers, Stef, Benghiat, Fleur Samantha, Gadisseur, Alain, Vanstraelen, Gaëtan, Vellemans, Hélène, Bailly, Benjamin, Granacher, Nikki, Lewalle, Philippe, De Becker, Ann, Van Eygen, Koen, Janssen, Mia, Triffet, Agnes, Vrelust, Inge, Deeren, Dries, Mazure, Dominiek, Bekaert, Julie, Beck, Michael, and Selleslag, Dominik

Published
2021
Full Text
View/download PDF

12. The crosstalk between lung cancer and the bone marrow niche fuels emergency myelopoiesis.

Author

Calderon-Espinosa, Evelyn, De Ridder, Kirsten, Benoot, Thomas, Jansen, Yanina, Vanhonacker, Domien, Heestermans, Robbe, De Becker, Ann, Van Riet, Ivan, Decoster, Lore, and Goyvaerts, Cleo

Subjects
BONE marrow cancer, EXTRAMEDULLARY hematopoiesis, HEMATOPOIETIC stem cells, CANCER patients, LUNG cancer
Abstract

Modest response rates to immunotherapy observed in advanced lung cancer patients underscore the need to identify reliable biomarkers and targets, enhancing both treatment decision-making and efficacy. Factors such as PD-L1 expression, tumor mutation burden, and a 'hot' tumor microenvironment with heightened effector T cell infiltration have consistently been associated with positive responses. In contrast, the predictive role of the abundantly present tumor-infiltrating myeloid cell (TIMs) fraction remains somewhat uncertain, partly explained by their towering variety in terms of ontogeny, phenotype, location, and function. Nevertheless, numerous preclinical and clinical studies established a clear link between lung cancer progression and alterations in intra- and extramedullary hematopoiesis, leading to emergency myelopoiesis at the expense of megakaryocyte/erythroid and lymphoid differentiation. These observations affirm that a continuous crosstalk between solid cancers such as lung cancer and the bone marrow niche (BMN) must take place. However, the BMN, encompassing hematopoietic stem and progenitor cells, differentiated immune and stromal cells, remains inadequately explored in solid cancer patients. Subsequently, no clear consensus has been reached on the exact breadth of tumor installed hematopoiesis perturbing cues nor their predictive power for immunotherapy. As the current era of single-cell omics is reshaping our understanding of the hematopoietic process and the subcluster landscape of lung TIMs, we aim to present an updated overview of the hierarchical differentiation process of TIMs within the BMN of solid cancer bearing subjects. Our comprehensive overview underscores that lung cancer should be regarded as a systemic disease in which the cues governing the lung tumor-BMN crosstalk might bolster the definition of new biomarkers and druggable targets, potentially mitigating the high attrition rate of leading immunotherapies for NSCLC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres

Author

Poirel, Hélène A., Vanspauwen, Marijke, Macq, Gilles, De Geyndt, Anke, Maertens, Johan, Willems, Evelyne, Selleslag, Dominik, Poiré, Xavier, Theunissen, Koen, Graux, Carlos, Kerre, Tessa, Zachée, Pierre, Meuleman, Nathalie, De Becker, Ann, Verlinden, Anke, Van Obbergh, Florence, Schuermans, Christine, De Wilde, Virginie, Jaspers, Aurélie, Pranger, Delphine, Deeren, Dries, Van Riet, Ivan, Vaes, Evelien, Beguin, Yves, and On behalf of the Belgian Transplant Registry and the Belgian Haematological Society’s Transplant committee

Published
2019
Full Text
View/download PDF

16. Disease Perception Is Correlated with Health-Related Quality of Life in Patients Suffering from Myelodysplastic Syndromes: Results of the Belgian Be-QUALMS Study

Author

Heyrman, Bert, primary, Meers, Stef, additional, De Becker, Ann, additional, Wouters, Kristien, additional, Van Hoof, Achiel, additional, Van De Velde, Ann, additional, Graux, Carlos, additional, Mazure, Dominiek, additional, Selleslag, Dominik, additional, Maes, Helena, additional, Lemmens, Jan, additional, Beckers, Marielle, additional, Breems, Dimitri, additional, Sid, Sélim, additional, Berneman, Zwi, additional, and Anguille, Sébastien, additional

Published
2023
Full Text
View/download PDF

19. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis

Author

Laureys, Guy, Willekens, Barbara, Vanopdenbosch, Ludo, Deryck, Olivier, Selleslag, Dominik, D’Haeseleer, Miguel, De Becker, Ann, Dubois, Bénédicte, Dierickx, Daan, Perrotta, Gaetano, De Wilde, Virginie, van Pesch, Vincent, Straetmans, Nicole, Dive, Dominique, Beguin, Yves, Van Wijmeersch, Bart, Theunissen, Koen, Kerre, Tessa, and Van de Velde, Ann

Published
2018
Full Text
View/download PDF

20. Outcome of SARS-CoV2 infection in hematopoietic stem cell transplant recipients for autoimmune diseases

Author

Greco, Raffaella, primary, Snowden, John A., additional, Knelange, Nina Simone, additional, Tridello, Gloria, additional, Cacciatore, Carlotta, additional, Xhaard, Alienor, additional, Ciceri, Fabio, additional, Collin, Matthew, additional, Ferra, Christelle, additional, De Becker, Ann, additional, Badoglio, Manuela, additional, Averbuch, Dina, additional, Alexander, Tobias, additional, Ljungman, Per, additional, and De la Camara, Rafael, additional

Published
2023
Full Text
View/download PDF

21. Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Servais, Sophie, Baron, Frédéric, Lechanteur, Chantal, Seidel, Laurence, Baudoux, Etienne, Briquet, Alexandra, Selleslag, Dominik, Maertens, Johan, Poire, Xavier, Schroyens, Wilfried, Graux, Carlos, De Becker, Ann, Zachee, Pierre, Ory, Aurélie, Herman, Julie, Kerre, Tessa, Beguin, Yves, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Servais, Sophie, Baron, Frédéric, Lechanteur, Chantal, Seidel, Laurence, Baudoux, Etienne, Briquet, Alexandra, Selleslag, Dominik, Maertens, Johan, Poire, Xavier, Schroyens, Wilfried, Graux, Carlos, De Becker, Ann, Zachee, Pierre, Ory, Aurélie, Herman, Julie, Kerre, Tessa, and Beguin, Yves

Abstract

Poor graft function (PGF) is a rare but serious complication of allogeneic hematopoietic cell transplantation (alloHCT). Due to their hematopoietic supporting properties and immune regulatory effects, multipotent mesenchymal stromal cells (MSC) could be considered a good candidate to help to restore bone marrow (BM) niches homeostasis and facilitate hematopoiesis after alloHCT. We prospectively assessed the efficacy and safety of ex-vivo expanded BM-derived MSC from third-party donor in a series of 30 patients with prolonged severe cytopenia and PGF after alloHCT. This multicenter trial was registered at www.clinicaltrials.gov (#NTC00603330). Within 90 days post-MSC infusion, 53% (95% CI, 35 - 71%) of patients improved at least one cytopenia (overall response, OR) and 37% (95% CI, 19 - 54%) achieved a complete hematological response (CR: absolute neutrophil count, ANC >0.5 x 10/L, Hb > 80g/L and platelet count > 20 x 10/L with transfusion independence). Corresponding response rates increased to 67% (95% CI, 50 - 84%) OR and 53% (95% CI, 35 - 71%) CR within 180 days after MSC infusion. A significant decrease in red blood cells and platelets transfusion requirement was observed after MSC (median of 30-days transfusion requirement of 0.5 and 0 from d90-120 post-MSC versus 5 and 6.5 before MSC, respectively, p ≤0.001). An increase in ANC was also noted by day +90 and +180, with 3/5 patients with severe neutropenia having recovered an ANC > 1 x 10/L within the 90-120 days after MSC infusion. Overall survival at 1 year post-MSC was 70% (95% CI, 55.4 - 88.5), with all but one of the patients who achieved CR being alive. A single infusion of third-party MSC appeared to be safe, with the exception of one deep vein thrombotic event possibly related to the intervention. In conclusion, a single i.v. infusion of BM-derived MSC from third party donor seemed to improve hematological function after alloHCT, although spontaneous amelioration cannot be excluded. Comparative studies a

Published
2023

23. Veno-venous extra-corporeal membrane oxygenation in a COVID-19 patient with cold-agglutinin haemolytic anaemia: A case report.

Author

Raes, Matthias, De Becker, Ann, Blanckaert, Jeroen, Balthazar, Tim, De Ridder, Simon, Mekeirele, Michael, Verbrugge, Frederik Hendrik, Poelaert, Jan, and Taccone, Fabio Silvio

Subjects
*RITUXIMAB, *ISCHEMIA, *COVID-19, *HOSPITAL emergency services, *ADRENOCORTICAL hormones, *EXTRACORPOREAL membrane oxygenation, *SEVERITY of illness index, *DYSPNEA, *ARTIFICIAL respiration, *DISEASE relapse, *COUGH, *INTESTINAL diseases, *CHOLANGITIS, *TERMINATION of treatment, *DEATH, *AUTOIMMUNE hemolytic anemia, *HYPOXEMIA, *TRACHEA intubation, *LIVER failure, *DISEASE complications
Abstract

Overview: The use of extra-corporeal membrane oxygenation (ECMO) therapy to treat severe COVID-19 patients with acute respiratory failure is increasing worldwide. We reported herein the use of veno-venous ECMO in a patient with cold agglutinin haemolytic anaemia (CAHA) who suffered from severe COVID-19 infection. Description: A 64-year-old man presented to the emergency department (ED) with incremental complaints of dyspnoea and cough since one week. His history consisted of CAHA, which responded well to corticosteroid treatment. Because of severe hypoxemia, urgent intubation and mechanical ventilation were necessary. Despite deep sedation, muscle paralysis and prone ventilation, P/F ratio remained low. Though his history of CAHA, he still was considered for VV-ECMO. As lab results pointed to recurrence of CAHA, corticosteroids and rituximab were started. The VV-ECMO run was short and rather uncomplicated. Although, despite treatment, CAHA persisted and caused important complications of intestinal ischemia, which needed multiple surgical interventions. Finally, the patient suffered from progressive liver failure, thought to be secondary to ischemic cholangitis. One month after admission, therapy was stopped and patient passed away. Conclusion: Our case report shows that CAHA is no contraindication for VV-ECMO, even when both titre and thermal amplitude are high. Although, the aetiology of CAHA and its response to therapy will determine the final outcome of those patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis

Author

Servais, Sophie, primary, Baron, Frédéric, additional, Lechanteur, Chantal, additional, Seidel, Laurence, additional, Baudoux, Etienne, additional, Briquet, Alexandra, additional, Selleslag, Dominik, additional, Maertens, Johan, additional, Poire, Xavier, additional, Schroyens, Wilfried, additional, Graux, Carlos, additional, De Becker, Ann, additional, Zachee, Pierre, additional, Ory, Aurélie, additional, Herman, Julie, additional, Kerre, Tessa, additional, and Beguin, Yves, additional

Published
2023
Full Text
View/download PDF

25. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Author

Drozd-Sokolowska, Joanna, primary, Gras, Luuk, additional, Zinger, Nienke, additional, Zahrani, Mohsen Al, additional, Passweg, Jakob, additional, Byrne, Jenny, additional, Ho, Aloysius, additional, Huang, Xiao-jun, additional, Kröger, Nicolaus, additional, Mayer, Jiri, additional, Russo, Domenico, additional, De Becker, Ann, additional, Tbakhi, Abdelghani, additional, Stamatoullas, Aspasia, additional, Valerius, Thomas, additional, Hayden, Patrick, additional, McLornan, Donal P., additional, Onida, Francesco, additional, Scheid, Christof, additional, Robin, Marie, additional, and Yakoub-Agha, Ibrahim, additional

Published
2022
Full Text
View/download PDF

26. Interim Results from Clevo: A Non-Interventional Cohort Study Investigating the Clonal Evolution of FMS-like Tyrosine Kinase 3 (FLT3) Mutations during Disease Progression in Patients with Acute Myeloid Leukemia

Author

Papayannidis, Cristina, primary, Boluda, Blanca, additional, Canaani, Jonathan, additional, Turlure, Pascal, additional, De Becker, Ann, additional, Tandra, Anand, additional, Elsouda, Dina, additional, Houweling, Arnaud, additional, Upadhyay, Anil, additional, Wouters, Isabelle, additional, and Vyas, Paresh, additional

Published
2022
Full Text
View/download PDF

30. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

Author

Lübbert, Michael, Wijermans, Pierre W, Kicinski, Michal, Chantepie, Sylvain, Van der Velden, Walter J F M, Noppeney, Richard, Griškevičius, Laimonas, Neubauer, Andreas, Crysandt, Martina, Vrhovac, Radovan, Luppi, Mario, Fuhrmann, Stephan, Audisio, Ernesta, Candoni, Anna, Legrand, Olivier, Foà, Robin, Gaidano, Gianluca, van Lammeren-Venema, Danielle, Posthuma, Eduardus F M, Hoogendoorn, Mels, Giraut, Anne, Stevens-Kroef, Marian, Jansen, Joop H, de Graaf, Aniek O, Efficace, Fabio, Ammatuna, Emanuele, Vilque, Jean-Pierre, Wäsch, Ralph, Becker, Heiko, Blijlevens, Nicole, Dührsen, Ulrich, Baron, Frédéric, Suciu, Stefan, Amadori, Sergio, Venditti, Adriano, Huls, Gerwin, Finke, Jürgen, Schaap, Nicolaas Petrus Michael, Zucenka, Andrius, Metzelder, Stephan, Jost, Edgar, Perić, Zinaida, Forghieri, Fabio, Allione, Bernadino, Martelli, Maurizio, Iori, Anna Paola, Wittnebel, Sebastian, Mengarelli, Andrea, Imovilli, Annalisa, Olivieri, Attilio, De Prijck, Bernard José Marie, van der Poel, Marjolein W.M., Junghanß, Christian, Salih, Helmut Rainer, Tafuri, Agostino, Guimarães, José Eduardo, Musso, Maurizio, De Fabritiis, Paolo, Chevallier, Patrice, Selleslag, Dominik Luc, Cascavilla, Nicola, Berneman, Zwi, Jaspers, Aurélie, Zuffa, Eliana, Vanstraelen, Gaëtan, Visani, Giuseppe, Cuijpers, Maria Louisa Henriëtte, De Becker, Ann, Mianulli, Anna Maria, Hackanson, Björn, Mihaylov, Georgi Georgiev, Martinelli, Giovanni, Paolini, Stefania, Zinzani, Pier Luigi, Henkes, Martin, Al-Ali, Haifa Kathrin, La Rosée, Paul, Chierichini, Anna, Cudillo, Laura, Specchia, Giorgina, Šimec, Njetočka Gredelj, Capalbo, Silvana Franca, Spinosa, Giuseppina, Molica, Stefano, and de Jonge-Peeters, Susan Dorothé

Abstract

Many older patients with acute myeloid leukaemia die or cannot undergo allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by intensive chemotherapy. We hypothesised that replacing intensive chemotherapy with decitabine monotherapy could improve outcomes.

Published
2023
Full Text
View/download PDF

32. Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS)

Author

Poiré, Xavier, primary, Graux, Carlos, additional, Ory, Aurélie, additional, Herman, Julie, additional, Baron, Frédéric, additional, Schoemans, Hélène, additional, Lewalle, Philippe, additional, De Becker, Ann, additional, Deeren, Dries, additional, Berneman, Zwi, additional, Kerre, Tessa, additional, Zachée, Pierre, additional, Selleslag, Dominik, additional, and Beguin, Yves, additional

Published
2021
Full Text
View/download PDF

33. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Devos, Timothy, Havelange, Violaine, Theunissen, Koen, Meers, Stef, Benghiat, Fleur Samantha, Gadisseur, Alain, Vanstraelen, Gaëtan, Vellemans, Hélène, Bailly, Benjamin, Granacher, Nikki, Lewalle, Philippe, De Becker, Ann, Van Eygen, Koen, Janssen, Mia, Triffet, Agnes, Vrelust, Inge, Deeren, Dries, Mazure, Dominiek, Bekaert, Julie, Beck, Michael, Selleslag, Dominik, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Devos, Timothy, Havelange, Violaine, Theunissen, Koen, Meers, Stef, Benghiat, Fleur Samantha, Gadisseur, Alain, Vanstraelen, Gaëtan, Vellemans, Hélène, Bailly, Benjamin, Granacher, Nikki, Lewalle, Philippe, De Becker, Ann, Van Eygen, Koen, Janssen, Mia, Triffet, Agnes, Vrelust, Inge, Deeren, Dries, Mazure, Dominiek, Bekaert, Julie, Beck, Michael, and Selleslag, Dominik

Abstract

Data on clinical use of ponatinib are limited. This prospective registry aimed to evaluate outcomes of ponatinib treatment in routine practice over 3 years (2016-2019) in Belgium (NCT03678454). Patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) were treated with ponatinib per current label. Fifty patients (33 CML and 17 Ph+ ALL) were enrolled. Fifty-five percent of CML and 29% of Ph+ ALL patients had received ≥3 prior tyrosine kinase inhibitors (TKIs). Reasons for starting ponatinib were intolerance (40%), relapse or refractoriness (28%) to previous TKIs, progression (16%), or T315I mutation (16%). Median follow-up was 15 months for CML and 4.5 months for Ph+ ALL patients. Best response was a major molecular response in 58% of CML and 41% of Ph+ ALL patients. Of 20 patients who started ponatinib due to intolerance to previous TKIs, 9 (64%) CML and 4 (67%) Ph+ ALL achieved a major molecular response. Three-year estimates of overall survival were 85.3% and 85.6%, respectively, in CML and Ph+ ALL patients; estimated progression-free survival was 81.6% and 48.9%. Adverse reactions were reported in 34 patients (68%); rash (26%) and dry skin (10%) were most common. Reported cardiovascular adverse reactions included vascular stenosis (3), arterial hypertension (2), chest pain (1), palpitations (1), and vascular occlusion (1). This Belgian registry confirms results from the PACE clinical trial and supports routine ponatinib use in CML and Ph+ ALL patients who are resistant or intolerant to previous TKIs or with the T315I mutation.

Published
2021

34. Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS).

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Poiré, Xavier, Graux, Carlos, Ory, Aurélie, Herman, Julie, Baron, Frédéric, Schoemans, Hélène, Lewalle, Philippe, De Becker, Ann, Deeren, Dries, Berneman, Zwi, Kerre, Tessa, Zachée, Pierre, Selleslag, Dominik, Beguin, Yves, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Poiré, Xavier, Graux, Carlos, Ory, Aurélie, Herman, Julie, Baron, Frédéric, Schoemans, Hélène, Lewalle, Philippe, De Becker, Ann, Deeren, Dries, Berneman, Zwi, Kerre, Tessa, Zachée, Pierre, Selleslag, Dominik, and Beguin, Yves

Published
2021

36. Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms

Author

Segers, Vincent F.M., Van Riet, Ivan, Andries, Luc J., Lemmens, Katrien, Demolder, Marc J., De Becker, Ann J.M.L., Kockx, Mark M., and De Keulenaer, Gilles W.

Subjects
Heart failure -- Research, Heart failure -- Analysis, Heart failure -- Risk factors, Biological sciences
Abstract

Circulating stem cells home within the myocardium, probably as the first step of a tissue regeneration process. This step requires adhesion to cardiac microvascular endothelium (CMVE). In this study, we studied mechanisms of adhesion between CMVE and mesenchymal stem cells (MSCs). Adhesion was studied in vitro and in vitro. Isolated 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate-labeled rat MSCs were allowed to adhere to cultured CMVE in static and dynamic conditions. Either CMVE or MSCs were pretreated with cytokines [IL-1[beta], IL-3, IL-6, stem cell factor, stromal cell-derived factor-1, or TNF-[alpha], 10 ng/ml]. Control or TNF-[alpha]-treated MSCs were injected intracavitarily in rat hearts in vivo. In baseline in vitro conditions, the number of MSCs that adhered to CMVE was highly dependent on the flow ,ate of the superfusing medium but remained significant at venous and capillary shear stress amplitudes. Activation of both CMVE and MSCs with TNF-[alpha] or IL-1[beta] before adhesion concentration dependently increased adhesion of MSCs at each studied level of shear stress. Consistently, in vivo, activation of MSCs with TNF-[alpha] before injection significantly enhanced cardiac homing of MSCs. TNF-[alpha]-induced adhesion could be completely blocked by pretreating either CMVE or MSCs with anti-VCAM-1 monoclonal antibodies but not by anti-ICAM-1 antibodies. Adhesion of circulating MSCs in the heart appears to be an endothelium-dependent process and is sensitive to modulation by activators of both MSCs and endothelium. Inflammation and the expression of VCAM-1 but not ICAM-1 on both cell types have a regulatory effect on MSC homing in the heart. cardiac regeneration; heart failure

Published
2006

38. Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature

Author

Delie, Anke, primary, Verlinden, Anke, additional, Beel, Karolien, additional, Deeren, Dries, additional, Mazure, Dominiek, additional, Baron, Frédéric, additional, Breems, Dimitri, additional, De Becker, Ann, additional, Graux, Carlos, additional, Lewalle, Philippe, additional, Maertens, Johan, additional, Poire, Xavier, additional, Schoemans, Helene, additional, Selleslag, Dominik, additional, Van Obbergh, Florence, additional, and Kerre, Tessa, additional

Published
2020
Full Text
View/download PDF

42. Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Author

Devos, Timothy, primary, Havelange, Violaine, additional, Theunissen, Koen, additional, Meers, Stef, additional, Benghiat, Fleur Samantha, additional, Gadisseur, Alain, additional, Vanstraelen, Gaëtan, additional, André, Marc, additional, Bailly, Benjamin, additional, Granacher, Nikki, additional, Lewalle, Philippe, additional, De Becker, Ann, additional, Van Eygen, Koen, additional, Lejeune, Marie, additional, Deeren, Dries, additional, Nifosi, Gianfilippo, additional, Triffet, Agnes, additional, Vrelust, Inge, additional, Bekaert, Julie, additional, Beck, Michael, additional, and Selleslag, Dominik, additional

Published
2019
Full Text
View/download PDF

43. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

Author

UCL - (SLuc) Service de neurologie, UCL - (SLuc) Service d'hématologie, UCL - SSS/IONS - Institute of NeuroScience, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - SSS/IREC/SLUC - Pôle St.-Luc, Laureys, Guy, Willekens, Barbara, Vanopdenbosch, Ludo, Deryck, Olivier, Selleslag, Dominik, D'Haeseleer, Miguel, De Becker, Ann, Dubois, Bénédicte, Dierickx, Daan, Perrotta, Gaetano, De Wilde, Virginie, Van Pesch, Vincent, Straetmans, Nicole, Dive, Dominique, Beguin, Yves, Van Wijmeersch, Bart, Theunissen, Koen, Kerre, Tessa, Van de Velde, Ann, UCL - (SLuc) Service de neurologie, UCL - (SLuc) Service d'hématologie, UCL - SSS/IONS - Institute of NeuroScience, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - SSS/IREC/SLUC - Pôle St.-Luc, Laureys, Guy, Willekens, Barbara, Vanopdenbosch, Ludo, Deryck, Olivier, Selleslag, Dominik, D'Haeseleer, Miguel, De Becker, Ann, Dubois, Bénédicte, Dierickx, Daan, Perrotta, Gaetano, De Wilde, Virginie, Van Pesch, Vincent, Straetmans, Nicole, Dive, Dominique, Beguin, Yves, Van Wijmeersch, Bart, Theunissen, Koen, Kerre, Tessa, and Van de Velde, Ann

Abstract

Multiple sclerosis is considered to be an immune mediated inflammatory disorder of the central nervous system. It mainly affects young, socioeconomic active patients. Although our armamentarium for this disease has significantly evolved in recent years some patients remain refractory to conventional therapies. In these cases, autologous hematopoietic stem cell transplantation can be considered as a therapeutic option. Decreasing morbidity, mortality, and increasing patient awareness have led to rising inquiry by our patients about this treatment option. With the aim of a standardized protocol and data registration, a Belgian working party on stem cell therapy in multiple sclerosis was established. In this paper, we report the consensus protocol of this working party on autologous hematopoietic stem cell transplantation in multiple sclerosis.

Published
2018

45. Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature

Author

Delie, Anke, Verlinden, Anke, Beel, Karolien, Deeren, Dries, Mazure, Dominiek, Baron, Frédéric, Breems, Dimitri, De Becker, Ann, Graux, Carlos, Lewalle, Philippe, Maertens, Johan, Poire, Xavier, Schoemans, Helene, Selleslag, Dominik, Van Obbergh, Florence, and Kerre, Tessa

Abstract

ABSTRACTBackground:Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option in both adult and pediatric patients with malignant and non-malignant hematological diseases.  Chimerism analysis, which determines the donor or recipient origin of hematopoietic cells in HSCT recipients, is an essential aspect of post-HSCT follow-up.Objectives:To review the current literature and develop Belgian consensus guidelines for the use of chimerism analysis in the standard of care after allogeneic HSCT.Methods: Non-systematic review of the literature in consultancy with the members of the BHS transplantation committee.Results: Clinical application with regards to prediction of graft failure or relapse as well as cell source are reviewed. A consensus guideline on the use of chimerism analysis after HSCT is presented.Conclusion: Monitoring of the dynamics or kinetics of a patient’s chimerism status by serial analysis at fixed time points, as well as on suspicion of relapse or graft failure, is needed to monitor engraftment levels, as well as disease control and possible relapse.

Published
2021
Full Text
View/download PDF

49. Listeria monocytogenesinfections in hematopoietic cell transplant recipients: clinical manifestations and risk factors: A multinational retrospective case control study of the Infectious Diseases Working Party (IDWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Author

Averbuch, Dina, Tridello, Gloria, Wendel, Lotus, Itälä-Remes, Maija, Oren, Ilana, Karas, Michal, Blijlevens, Nicole, Beguin, Yves, Broers, Annoek, Calore, Elisabetta, Cattaneo, Chiara, Isaksson, Cecilia, Robin, Christine, Gadisseur, Alain, Maertens, Johan, De Becker, Ann, Lueck, Catherina, Metafuni, Elisabetta, Pichler, Herbert, Popova, Marina, Ram, Ron, Yeshurun, Moshe, Mikulska, Malgorzata, Camara, Rafael de la, and Styczynski, Jan

Abstract

•Listeriosis post-HSCT can cause septic shock, meningo-encephalitis, and mortality. Neurolisteriosis can present with non-specific signs and normal imaging.•Lymphocytopenia and non-first HSCT are associated with increased risk of listeriosis. Cotrimoxazole prophylaxis was not protective.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results